Veracyte delivered strong financial results in Q4 2024, with total revenue increasing by 21% year-over-year to $118.6 million. The company's net income reached $5.1 million, compared to a net loss in the prior year. Adjusted EBITDA rose to $26.1 million, representing 22% of revenue. The testing business continued to drive growth, with a 24% increase in testing revenue and a 25% rise in testing volume. Looking ahead, Veracyte expects continued momentum in 2025, particularly in its Decipher and Afirma product lines.
Q4 revenue grew 21% year-over-year to $118.6 million.
Testing revenue increased 24% to $112.2 million, with a 25% rise in volume.
Net income reached $5.1 million, reversing a loss from the prior year.
Adjusted EBITDA increased to $26.1 million, or 22% of revenue.
Veracyte expects 2025 testing revenue to grow by 12-15%, reaching $470-480 million. Adjusted EBITDA margin is forecasted to be approximately 21.6%. The company is also exploring options for its French subsidiary operations, which could impact future revenue guidance.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance